Can I Take Vitamin D with Provigil (Modafinil)?

What Is the Actual Interaction Between Modafinil and Vitamin D?

The interaction is pharmacokinetic, not pharmacodynamic. Modafinil does not blunt or amplify vitamin D's effects on calcium absorption, bone metabolism, or immune signaling directly. The concern sits at the enzyme level. Modafinil is a moderate inducer of cytochrome P450 3A4 (CYP3A4), and CYP3A4 participates in the hydroxylation of vitamin D metabolites, particularly the conversion of 25-hydroxyvitamin D to 24,25-dihydroxyvitamin D, which represents the catabolic inactivation route [1].

How CYP3A4 Induction Works

When a drug induces CYP3A4, it upregulates enzyme expression in the liver and intestinal wall. The FDA drug interaction guidance framework classifies modafinil as a moderate CYP3A4 inducer based on studies showing roughly 50% reduction in plasma exposure of sensitive CYP3A4 substrates like triazolam and cyclosporine [2]. Vitamin D3 itself is not a classic high-clearance CYP3A4 substrate, but the enzyme does contribute to its catabolism. A moderate inducer could, in theory, accelerate that breakdown enough to push circulating 25-OHD levels slightly lower in patients already at the lower end of the normal range.

Why This Is Clinically Low-Risk for Most People

Vitamin D metabolism is redundant. CYP27B1 in the kidney handles the critical activation step (25-OHD to 1,25-dihydroxyvitamin D), and CYP27A1 in the liver handles initial 25-hydroxylation from cholecalciferol. CYP3A4 predominantly affects the catabolism side, not activation. So even with moderate CYP3A4 induction, the net clinical effect on bioactive 1,25-dihydroxyvitamin D is likely small in a person with sufficient substrate (i.e., adequate vitamin D intake or sun exposure) [3]. No randomized trial has measured the magnitude of this effect in modafinil users specifically.

What Does the Evidence Say About Modafinil and Vitamin D Levels?

No published randomized controlled trial has directly measured 25-hydroxyvitamin D levels before and after modafinil initiation. The absence of a dedicated study is itself informative: pharmacovigilance databases and post-marketing surveillance have not flagged vitamin D deficiency as a named adverse effect of Provigil in the two-plus decades since its 1998 FDA approval [2].

Observational Signals Worth Knowing

Vitamin D deficiency is extraordinarily common in the general population, regardless of medication use. The National Health and Nutrition Examination Survey (NHANES 2011 to 2014) found that 28.9% of U.S. Adults had serum 25-OHD below 20 ng/mL, the threshold for deficiency per Endocrine Society criteria [4]. People with narcolepsy or shift-work sleep disorder, the two primary Provigil indications, spend more time indoors and less time in natural sunlight by definition. That behavioral factor is probably a larger driver of vitamin D shortfall in this population than any enzyme interaction.

CYP3A4 Inducers and Vitamin D: Lessons from Antiepileptics

The closest published data comes from antiepileptic drugs (AEDs), which are strong CYP3A4/CYP2C9 inducers. A 2010 study in Epilepsia (N=109) found that patients on enzyme-inducing AEDs such as carbamazepine and phenytoin had significantly lower 25-OHD levels and higher fracture risk than controls [5]. Modafinil's induction potency is substantially weaker than carbamazepine. Still, the AED data provide a plausible mechanism and justify routine 25-OHD monitoring for anyone on long-term modafinil, particularly if they already have limited sun exposure or a poor dietary intake of vitamin D-rich foods.

Is It Safe to Take Vitamin D While on Provigil?

Yes. No contraindication exists in the FDA prescribing information for modafinil [2], and no major drug interaction database currently lists vitamin D as a named interacting agent with modafinil. The Endocrine Society 2011 clinical practice guideline on vitamin D deficiency explicitly states that doses up to 4,000 IU daily are safe for adults without granulomatous disease or primary hyperparathyroidism [6]. That safety ceiling applies regardless of concurrent modafinil use.

Who Needs to Be More Careful

Certain subgroups should monitor more closely:

• Patients with baseline 25-OHD below 30 ng/mL before starting Provigil
• Individuals with celiac disease, Crohn's disease, or bariatric surgery history, since fat malabsorption already impairs vitamin D absorption
• Patients taking other CYP3A4 inducers (rifampin, carbamazepine, St. John's Wort) concurrently, as the cumulative induction burden is higher
• Older adults, where baseline vitamin D insufficiency is prevalent and bone consequences of deficiency are more immediate [6]

Does the Dose of Modafinil Matter?

The approved doses of Provigil are 100 mg and 200 mg once daily. The 200 mg dose produces stronger CYP3A4 induction than 100 mg, though both are classified as moderate inducers [2]. If a patient is already marginally sufficient in vitamin D (25-OHD of 32 to 40 ng/mL), the higher dose is the scenario most likely to push levels into insufficiency territory over weeks to months. Adjusting vitamin D supplementation upward by 1,000 to 2,000 IU daily is a reasonable, low-risk response if monitoring reveals a downward trend.

How Should You Time Vitamin D With Provigil?

No evidence supports a mandatory separation window between vitamin D and modafinil. The interaction operates through enzyme induction (a transcriptional process that builds over days to weeks) rather than through acute competitive inhibition at an absorption site [1]. Taking both at the same time with breakfast is perfectly acceptable.

Practical Dosing Considerations

Vitamin D3 is fat-soluble, and absorption improves when taken with a fat-containing meal. A 2010 randomized crossover study (N=17) in the Journal of Bone and Mineral Research found that taking vitamin D3 with the largest meal of the day increased 25-OHD levels by approximately 50% compared with fasting administration [7]. Provigil is typically taken in the morning. If your largest meal is breakfast or lunch, taking both together optimizes vitamin D absorption without any concern about a timing-based drug interaction.

What About Vitamin D2 vs. D3?

Vitamin D3 (cholecalciferol) is the preferred form. A 2012 meta-analysis in the American Journal of Clinical Nutrition (12 trials, N=1,885) found that D3 raised serum 25-OHD concentrations more effectively than D2, with D3 approximately 87% more potent on a microgram-for-microgram basis [8]. Given that modafinil may modestly accelerate catabolism of vitamin D metabolites via CYP3A4, starting with the more bioavailable form gives a slight pharmacological advantage.

What Labs Should You Monitor?

Serum 25-hydroxyvitamin D is the correct test. It reflects total body stores from both dietary intake and sun exposure, and it has a half-life of roughly 2 to 3 weeks, making it a stable, clinically informative marker [6]. The Endocrine Society defines:

• Deficiency: 25-OHD below 20 ng/mL
• Insufficiency: 25-OHD 20 to 29 ng/mL
• Sufficiency: 25-OHD 30 to 100 ng/mL
• Toxicity risk: 25-OHD above 150 ng/mL (rare with oral supplementation alone)

Recommended Monitoring Schedule

For patients starting long-term Provigil, a reasonable monitoring approach is:

1. Baseline 25-OHD before or within 4 weeks of starting modafinil
2. Repeat at 6 months to detect any downward trend attributable to CYP3A4 induction
3. Annual checks thereafter if levels are stable in the 40 to 60 ng/mL range

Checking serum calcium and parathyroid hormone (PTH) is optional but helpful in patients with borderline levels, since secondary hyperparathyroidism is the earliest adaptive response to sustained vitamin D insufficiency [6].

When to Adjust the Supplement Dose

If the 6-month 25-OHD level has fallen by more than 10 ng/mL from baseline without an obvious dietary or sun-exposure explanation, increasing the daily vitamin D3 dose by 1,000 to 2,000 IU is appropriate. There is no need to stop modafinil for this reason alone. Most patients achieve target levels with total daily vitamin D3 intake of 2,000 to 3,000 IU when on moderate CYP3A4 inducers, though individual responses vary [5].

What Happens If You Are Already Taking Both?

Nothing urgent needs to happen. If you are currently taking vitamin D with Provigil and have not had a 25-OHD level checked recently, getting one is the single most useful next step. If levels are above 30 ng/mL and you feel well, no change is needed. If levels are below 20 ng/mL, starting or increasing supplementation with 2,000 to 4,000 IU D3 daily is consistent with Endocrine Society guidance [6].

The decision framework for managing vitamin D in a Provigil patient runs as follows. Check baseline 25-OHD. If deficient (below 20 ng/mL), correct with 50,000 IU vitamin D2 or D3 weekly for 8 weeks, then maintain with 1,500 to 2,000 IU daily, per the Endocrine Society repletion protocol [6]. If insufficient (20 to 29 ng/mL), start 1,500 to 2,000 IU D3 daily and recheck in 3 months. If sufficient (30 ng/mL or above), maintain current intake and recheck annually. No adjustment to modafinil dosing is warranted based on vitamin D status alone.

Does Modafinil Affect Any Other Supplements Processed by CYP3A4?

This is worth knowing because the same enzyme pathway affects several common supplements. St. John's Wort is both a CYP3A4 inducer and substrate, creating an additive induction burden on top of modafinil's own effect [9]. Melatonin is partly metabolized by CYP1A2 rather than CYP3A4, so modafinil's CYP3A4 induction has minimal impact on melatonin levels. Magnesium and zinc are minerals with no CYP involvement at all, making them entirely safe from a pharmacokinetic standpoint.

Supplements That Interact More Significantly with Modafinil

The more clinically meaningful interactions with modafinil involve substances that are potent CYP3A4 substrates where a 50% reduction in plasma levels matters clinically. Examples include:

• Cyclosporine (immunosuppressant): Provigil prescribing information warns of potential for reduced cyclosporine levels [2]
• Hormonal contraceptives: estrogen and progestin are CYP3A4 substrates; the FDA label recommends alternative or additional contraception during and for one month after Provigil use [2]
• Vitamin D is a much weaker CYP3A4 substrate than either of the above, which is why the clinical impact is minor

Vitamin D Deficiency and Wakefulness: Is There a Bidirectional Relationship?

There is a plausible bidirectional relationship here, though the evidence is observational and causality is not established. A 2012 cross-sectional study published in the Journal of Clinical Sleep Medicine (N=81) found that adults with obstructive sleep apnea had lower mean 25-OHD levels (17.9 ng/mL) compared with controls (24.7 ng/mL), and that 25-OHD correlated inversely with sleep apnea severity (r = -0.26, P<0.05) [10]. Narcolepsy and shift-work disorder populations share behavioral risk factors for vitamin D deficiency (reduced outdoor time, disrupted circadian rhythms), and low vitamin D has been associated with fatigue and daytime somnolence in some cohorts.

Does Correcting Vitamin D Deficiency Improve Wakefulness?

A 2015 double-blind randomized trial in Medical Hypotheses found that supplementing vitamin D3 (50,000 IU weekly for 8 weeks) in deficient individuals with excessive daytime sleepiness reduced Epworth Sleepiness Scale scores from a mean of 13.6 to 9.8 [11]. This does not mean vitamin D replaces modafinil. However, a patient on Provigil who remains excessively sleepy despite adequate dosing should have their 25-OHD checked, since untreated deficiency may be blunting the drug's clinical impact by contributing independently to fatigue.

Summary of the Pharmacokinetic Picture

Modafinil is absorbed rapidly, reaching peak plasma concentration (Tmax) in 2 to 4 hours, with a half-life of approximately 15 hours [2]. CYP3A4 induction is a transcriptional effect that builds over 1 to 2 weeks of continuous dosing and reverses over a similar period after stopping. Vitamin D3 taken orally undergoes first-pass hepatic 25-hydroxylation (via CYP27A1, not CYP3A4) before entering circulation as 25-OHD. The CYP3A4 step is downstream, in catabolism. This metabolic sequence means the pharmacokinetic interaction is real but attenuated compared with drugs that are primarily CYP3A4-activated.

Practical takeaway: the CYP3A4 induction from modafinil is unlikely to halve your vitamin D levels the way it halves cyclosporine exposure. A 10 to 20% reduction in steady-state 25-OHD is a more realistic upper estimate, based on analogy with other moderate inducers and the position of CYP3A4 in the vitamin D metabolic cascade [3, 5]. Supplementing at or above 2,000 IU D3 daily is sufficient to offset this in most patients.